BMJ Case Reports 2009; doi:10.1136/bcr.08.2008.0761
  • Unexpected outcome (positive or negative) including adverse drug reactions

Severe drug induced acute hepatitis associated with use of St John’s wort (Hypericum perforatum) during treatment with pegylated interferon α

  1. Paola Piccolo1,
  2. Silvia Gentile2,
  3. Filippo Alegiani2,
  4. Mario Angelico1
  1. 1
    Tor Vergata University, Hepaotology Unit, via Montpellier, Rome, 00135, Italy
  2. 2
    Fatebenefratelli Hospital, Isola Tiberina, Rome, 00186, Italy
  1. Paola Piccolo, paola.piccolo{at}
  • Published 14 April 2009


A 61-year-old woman with chronic hepatitis C received peginterferon α 180 μg/week, and obtained undetectable qualitative hepatitis C virus (HCV) RNA (lower limit of detection 50 IU/ml) after 8 weeks of treatment. Shortly thereafter aminotransferase values greatly increased (>20 × upper limit of normal) and did not decline after treatment suspension. The patient admitted taking St John’s wort (Hypericum perforatum) for depressed mood, recommended by a friend, during the preceding 6 weeks. Liver function tests continued to worsen and international normalised ratio (INR) prolongation developed; the patient was hospitalised. Test for antinuclear antibody was positive (1:320) and treatment with methylprednisolone was started; bilirubin and aminotransferase levels slowly declined, though a new flare occurred when steroids were tapered. After 6 months of prednisone treatment, the liver function tests returned to baseline levels. The combination of peginterferon α and St John’s wort resulted in a severe acute hepatitis in this patient. Patients should be advised of this potential toxic effect of this herbal remedy.


  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article